EligibleTrials

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

Recruiting · NCT05059158 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ludwig-Maximilians - University of Munich

View the official record on ClinicalTrials.gov →
Alzheimer's disease

Interventions studied

positron emission tomography (PET)

What this trial is about

The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.

Who can take part

Age range
50 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.